Wednesday, February 18, 2026
CN
  • About
  • Advertise
  • Careers
  • Contact
Money Compass
  • Home
  • Financial News
  • Investment News
  • Other News
    • Bursa News
    • Government News
    • Listing Companies News
    • Oversea Financial & Investment News
  • Interviews
    • Features Interviews
    • Corporate Interviews
  • Financial & Investment Articles
  • PR Newswire
  • Login
No Result
View All Result
Money Compass
Home PR Newswire

HUMAIN Backs xAI with $3 Billion Series E Investment Ahead of Historic SpaceX Merger

Money Compass by Money Compass
February 18, 2026
in PR Newswire
0
HUMAIN Backs xAI with $3 Billion Series E Investment Ahead of Historic SpaceX Merger
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter
  • HUMAIN invested $3 billion in xAI’s Series E round just prior to its acquisition by SpaceX, positioning itself at a pivotal moment of platform-scale expansion and integration
  • As a result of the transaction, HUMAIN became a significant minority shareholder, with its xAI holdings converted into SpaceX shares
  • The investment builds on HUMAIN and xAI’s 500MW AI infrastructure partnership in Saudi Arabia, reinforcing HUMAIN’s role as both a strategic development partner and a leading global investor in frontier AI technologies

RIYADH, Saudi Arabia, Feb. 18, 2026 /PRNewswire/ — HUMAIN, a PIF company delivering full-stack artificial intelligence capabilities globally, today announced a $3 billion strategic investment in xAI as part of the company’s Series E financing round. The transaction represents a significant, end-to-end capital deployment for HUMAIN, reflecting continued momentum in its long-term investment strategy focused on category-defining technology platforms.

 

Related posts

FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens

FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens

February 18, 2026
FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens

FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens

February 18, 2026
HUMAIN Backs xAI with $3 Billion Series E Investment Ahead of Historic SpaceX Merger

 

The investment comes at a highly compelling inflection point for xAI, preceding its acquisition by SpaceX in early February. The combination of xAI’s advanced artificial intelligence capabilities with SpaceX’s scale, infrastructure, and mission-driven engineering creates a uniquely positioned platform for accelerated growth, deep technological integration, and long-term value creation.

As a result of the Series E transaction, HUMAIN became a significant minority shareholder in xAI, with its holdings subsequently converted into shares in SpaceX. The transaction creates a solid platform for HUMAIN’s exposure to long-term equity upside, reflecting participation in xAI’s final financing round ahead of the merger.

“This investment reflects HUMAIN’s conviction in transformational AI and our ability to deploy meaningful capital behind exceptional opportunities where long-term vision, technical excellence, and execution converge,” said Tareq Amin, CEO of HUMAIN. “xAI’s trajectory, further strengthened by its acquisition by SpaceX, one of the largest technology mergers on record, represents the kind of high-impact platform we seek to support with significant capital.”

HUMAIN’s participation in the Series E round reinforces its role as a scaled, long-term strategic investor capable of supporting companies across multiple stages of growth, while delivering full-stack AI capabilities across four core areas: next-generation data centers; high-performance infrastructure and cloud platforms; advanced AI models; and transformative AI solutions.

The investment builds on the large-scale partnership announced in November 2025 at the U.S.-Saudi Investment Forum, under which HUMAIN and xAI committed to jointly develop more than 500MW of next-generation AI data center and compute infrastructure and to deploy xAI’s Grok models in Saudi Arabia. Together, these initiatives deepen long-term alignment and extend HUMAIN’s role from strategic partner to leading global shareholder in xAI.

Looking ahead, HUMAIN’s strategy includes the pursuit of additional investments across artificial intelligence, frontier technologies, and critical infrastructure.

About HUMAIN

HUMAIN, a PIF company, is a global artificial intelligence company delivering full-stack AI capabilities across four core areas: next-generation data centers; hyper-performance infrastructure and cloud platforms; advanced AI models, including some of the world’s most advanced Arabic large language models developed in the Arab world; and transformative AI solutions that combine deep sector insight with real-world execution.

HUMAIN’s end-to-end model serves both public and private sector organizations, unlocking value across industries, driving digital transformation, and strengthening capabilities through human–AI collaboration. With a growing portfolio of sector-specific AI products and a core mission focused on intellectual property development and global talent leadership, HUMAIN is engineered for international competitiveness and technological excellence.

Forward-Looking Statement:

This press release may contain forward-looking statements based on current expectations and assumptions. Actual results may differ materially due to various risks and uncertainties. HUMAIN undertakes no obligation to update these statements.

 

HUMAIN Logo

 

Media Inquiries:
For further details about HUMAIN, please visit humain.com.
For Media inquiries, please contact:
Hana Nemec, Head of Communications & PR
[email protected]
Follow HUMAIN on: X | LinkedIn

SOURCE HUMAIN

​ 

Previous Post

Milo Crosses $100 Million Crypto Mortgage Milestone, Closes Record $12 Million Transaction

Next Post

FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens

Next Post
FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens

FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

BROWSE BY CATEGORIES

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire

BROWSE BY TOPICS

2018 League Balinese Culture Bali United Budget Travel business Champions League Chopper Bike Doctor Terawan industrial Istana Negara Malaysia Market Stories National Exam net zero emissions targets 2025 Renewable energy Visit Bali

Recent News

  • FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens
  • FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens
  • HUMAIN Backs xAI with $3 Billion Series E Investment Ahead of Historic SpaceX Merger

Category

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire
  • About
  • Advertise
  • Careers
  • Contact

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Features Interviews
  • Government News
  • Financial News
  • Investment News
  • Listing Companies News
  • Corporate Interviews
  • Bursa News
  • Financial & Investment Articles
  • Oversea Financial & Investment News

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved